Access Vascular, Inc. today announced FDA clearance of its HydroMID™ midline catheter. HydroMID, which is made of Access Vascular’s proprietary biomaterial that has been shown to reduce thrombus accumulation by up to 97 percent when compared to standard polyurethane catheters,1 is the second device in its planned portfolio to obtain clearance.
Midline catheters have grown in popularity due to inclusion in the MAGIC (Michigan Appropriateness Guide to Intravenous Catheters) guidelines, and the elimination of the need for confirmatory chest X-rays for midline placement. Standard midlines are composed of polyurethanes or silicones, which may lead to protein adsorption.2 This can result in thrombus accumulation3 or catheter-related infections.4
HydroMID is a 4 French, single lumen, midline catheter with a maximum usable length of 20cm. HydroMID will be made available over the next few weeks to gain clinical feedback on the usage of this midline catheter.